Evaluation of drug-drug interactions in hospitalized patients on medications for OUD

• DOI: 10.9740/mhc.2021.07.231
• Publication Date: 2021-07-16T17:41:00Z
• Authors: Olivia Berger; Katherine Rector; Jacqueline Meredith; Jamielynn Sebaaly
• Keywords: Depression; Pharmacodynamics

Medications used to treat OUD have common metabolic pathways and pharmacodynamic properties that can lead drug-drug interactions (DDIs) may go unnoticed in the inpatient setting. The purpose of this study was identify frequency DDIs between medications prescribed for commonly medications.This a retrospective review orders buprenorphine, buprenorphine-naloxone, methadone potential DDIs. Adult inpatients with an order one these were included. Medication regimens evaluated throughout stay on day discharge classified by severity type interaction (increased risk QT prolongation, additive CNS effects/respiratory depression, opioid withdrawal). primary endpoint number Other endpoints included each classification/severity DDI, duration therapy interacting medications, modifications made because DDIs.A total 102 patients included, 215 83 at identified. While inpatient, 85% medication, 46% medication discharge. most classification DDI depression (68.8% 50.6% discharge), followed prolongation (24.2% 45.8% discharge). majority as requiring close monitoring rather than contraindicated.There are opportunities optimize prescribing practices surrounding both setting ensure patient safety.